Twist Bioscience (TWST) Projected to Post Earnings on Monday

Twist Bioscience (NASDAQ:TWST) is anticipated to announce its Q1 2026 results before the market opens on Monday, February 2nd. Analysts expect Twist Bioscience to post earnings of ($0.49) per share and revenue of $100.3160 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:00 AM ET.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The firm had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Stock Performance

Shares of TWST opened at $41.07 on Friday. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. The stock has a 50-day moving average price of $35.25 and a 200-day moving average price of $31.63. The company has a market cap of $2.52 billion, a PE ratio of -31.35 and a beta of 2.19. Twist Bioscience has a 12-month low of $23.30 and a 12-month high of $54.74.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TWST shares. Barclays boosted their price objective on shares of Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Stephens began coverage on Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Evercore ISI reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Twist Bioscience in a research report on Monday, January 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.67.

Insider Buying and Selling at Twist Bioscience

In other news, CFO Adam Laponis sold 3,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00. Following the completion of the sale, the chief financial officer owned 137,031 shares of the company’s stock, valued at $5,481,240. The trade was a 2.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Dennis Cho sold 1,019 shares of Twist Bioscience stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total transaction of $32,689.52. Following the transaction, the insider owned 120,694 shares in the company, valued at approximately $3,871,863.52. This trade represents a 0.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 15,090 shares of company stock worth $522,015 over the last 90 days. 3.08% of the stock is owned by company insiders.

Institutional Trading of Twist Bioscience

A number of large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in shares of Twist Bioscience by 11.8% in the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock worth $1,585,000 after purchasing an additional 4,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after buying an additional 3,181 shares during the period. Goldman Sachs Group Inc. increased its position in Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after purchasing an additional 37,577 shares during the period. Intech Investment Management LLC increased its holdings in Twist Bioscience by 18.9% during the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after buying an additional 4,591 shares during the period. Finally, Norges Bank bought a new stake in Twist Bioscience during the 2nd quarter valued at $737,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.